Impact of lung function on exacerbations, health care utilization, and costs among patients with COPD

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 1689-1703

  Ke, Xuehua ^a   Marvel, Jessica ^b   Yu, Tzy Chyi ^b   Wertz, Debra ^a   Geremakis, Caroline ^a   Wang, Liya ^a   Stephenson, Judith J ^a   Mannino, David M ^c  

^a HEALTHCORE INC   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

COPD; Exacerbations; FEV1; Health care resource utilization and costs; Lung function

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; MUSCARINIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE IV INHIBITOR; XANTHENE DERIVATIVE; BRONCHODILATING AGENT;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREVALENCE; RESPIRATORY TRACT PARAMETERS; RETROSPECTIVE STUDY; SPIROMETRY; ADMINISTRATIVE CLAIMS (HEALTH CARE); AMBULATORY CARE; DISEASE COURSE; DRUG COST; ECONOMICS; FACTUAL DATABASE; HEALTH CARE PLANNING; HOSPITAL COST; HOSPITAL EMERGENCY SERVICE; HOSPITALIZATION; LUNG; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; UTILIZATION; VERY ELDERLY;

ADMINISTRATIVE CLAIMS, HEALTHCARE; ADULT; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; DATABASES, FACTUAL; DISEASE PROGRESSION; DRUG COSTS; EMERGENCY SERVICE, HOSPITAL; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH CARE COSTS; HEALTH RESOURCES; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; LINEAR MODELS; LOGISTIC MODELS; LUNG; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; OFFICE VISITS; PREDICTIVE VALUE OF TESTS; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPIROMETRY; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84983035699     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S108967     Document Type: Article

References (46)

1. Dewar M, Curry RW Jr. Chronic obstructive pulmonary disease: diagnostic considerations. Am Fam Physician. 2006;73(4):669–676.
2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of COPD. Bethesda (MD): GOLD; 2014.
3. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Al M, Molken MR. Association between lung function and exacerbation frequency in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2010;5:435–444.
4. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax. 2001;56(11):880–887.
5. Solem CT, Sun SX, Liu S, et al. Comparison of disease-severity measures within severe and very severe COPD patients: results from a nationally representative chart review and patient survey. Int J Chron Obstruct Pulmon Dis. 2014;9:991–998.
6. Westwood M, Bourbeau J, Jones PW, Cerulli A, Capkun-Niggli G, Worthy G. Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review. Respir Res. 2011;12:40.
7. Anzueto A, Leimer I, Kesten S. Impact of frequency of COPD exacerbations on pulmonary function, health status and clinical outcomes. Int J Chron Obstruct Pulmon Dis. 2009;4:245–251.
8. Groenewegen KH, Postma DS, Hop WC, et al. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest. 2008;133(2):350–357.
9. Gudmundsson G, Gislason T, Janson C, et al. Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur Respir J. 2005;26(3):414–419.
10. Gudmundsson G, Gislason T, Lindberg E, et al. Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respir Res. 2006;7:109.
11. Jones PW, Donohue JF, Nedelman J, Pascoe S, Pinault G, Lassen C. Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir Res. 2011;12:161.
12. Mannino DM, Davis KJ. Lung function decline and outcomes in an elderly population. Thorax. 2006;61(6):472–477.
13. McGlone S, Venn A, Walters EH, Wood-Baker R. Physical activity, spirometry and quality-of-life in chronic obstructive pulmonary disease. COPD. 2006;3(2):83–88.
14. Niewoehner DE. Relation of chronic obstructive pulmonary disease exacerbations to FEV(1) – an intricate tango. Respiration. 2009;77(2):229–235.
15. Omata M, Wakabayashi R, Kudoh S, Kida K. Correlation between bronchodilator responsiveness and quality of life in chronic obstructive pulmonary disease. Allergol Int. 2007;56(1):15–22.
16. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161(5):1608–1613.
17. Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ. 2011;14(3):315–323.
18. Jansson SA, Andersson F, Borg S, Ericsson A, Jönsson E, Lundbäck B. Costs of COPD in Sweden according to disease severity. Chest. 2002;122(6):1994–2002.
19. Jansson SA, Backman H, Stenling A, Lindberg A, Rönmark E, Lundbäck B. Health economic costs of COPD in Sweden by disease severity – has it changed during a ten years period? Respir Med. 2013;107(12):1931–1938.
20. Chung K, Kim K, Jung J, et al. Patterns and determinants of COPD-related healthcare utilization by severity of airway obstruction in Korea. BMC Pulm Med. 2014;14:27.
21. Diez JM, Garrido PC, Carballo MG, et al. Determinants and predictors of the cost of COPD in primary care: a Spanish perspective. Int J Chron Obstruct Pulmon Dis. 2008;3(4):701–712.
22. Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest. 2000;118(5):1278–1285.
23. Koleva D, Mortterlini N, Banfi P, Garattini L. Healthcare costs of COPD in Italian referral centres: a prospective study. Respir Med. 2007;101(11):2312–2320.
24. Lacasse Y, Daigle JM, Martin SK, Maltais F. Validity of chronic obstructive pulmonary disease diagnoses in a large administrative database. Can Respir J. 2012;19(2):e5–e9.
25. Maleki-Yazdi M, Kelly SM, Lam SS, Marin M, Barbeau M, Walker V. The burden of illness in patients with moderate to severe chronic obstructive pulmonary disease in Canada. Can Respir J. 2012;19(5):319–324.
26. Mapel DW, McMillan GP, Frost FJ, et al. Predicting the costs of managing patients with chronic pulmonary disease. Respir Med. 2005;99(10):1325–1333.
27. Mapel DW, Roberts M. Spirometry, the St. George’s Respiratory Questionnaire, and other clinical measures as predictors of medical costs and COPD exacerbation events in a prospective cohort. Southwest Respir Crit Care Chron. 2015;3(10):1–9.
28. Menn P, Heinrich J, Huber RM, et al. Direct medical costs of COPD – an excess cost approach based on two population-based studies. Respir Med. 2012;106(4):540–548.
29. Miravitlles M, Murio C, Guerrero T, Gisbert R. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest. 2003;123(3):784–791.
30. Nielsen R, Johannessen A, Omenaas ER, Bakke PS, Askildsen JE, Gulsvik A. Excessive costs of COPD in ever-smokers: a longitudinal community study. Respir Med. 2011;105(3):485–493.
31. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–1139.
32. Bureau of Labor Statistics. Databases, tables & calculators by subject. Available from: http://data.bls.gov/timeseries/CUUR0000SAM?output_view=pct_12mths. Accessed September 10, 2015.
33. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med. 2000;160(11):1683–1689.
34. Louie S, Zeki AA, Schivo M, et al. The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations. Expert Rev Clin Pharmacol. 2013;6(2):197–219.
35. McDonald VM, Simpson JL, Higgins I, Gibson PG. Multidimensional assessment of older people with asthma and COPD: clinical management and health status. Age Ageing. 2011;40(1):42–49.
36. Soriano JB, Davis KJ, Coleman B, Visick G, Mannino D, Pride NB. The proportional Venn diagram of obstructive lung disease: two approximations from the United States and the United Kingdom. Chest. 2003;124(2):474–481.
37. Baker CL, Zou KH, Su J. Risk assessment of readmissions following an initial COPD-related hospitalization. Int J Chron Obstruct Pulmon Dis. 2013;8:551–559.
38. Blasi F, Cesana G, Conti S, et al. The clinical and economic impact of exacerbations of chronic obstructive pulmonary disease: a cohort of hospitalized patients. PLoS One. 2014;9(6):e101228.
39. Fan VS, Ramsey SD, Make BJ, Martinez FJ. Physiologic variables and functional status independently predict COPD hospitalizations and emergency department visits in patients with severe COPD. COPD. 2007;4(1):29–39.
40. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138.
41. Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–963.
42. Aaron SD. Management and prevention of exacerbations of COPD. BMJ. 2014;349:g5237.
43. Agusti A, Calverley PM, Decramer M, Stockley RA, Wedzicha JA. Prevention of exacerbations in chronic obstructive pulmonary disease: knowns and unknowns. Chronic Obstr Pulm Dis (Miami). 2014;1(2):166–184.
44. Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013;1(7):524–533.
45. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093–1103.
46. Drivenes E, Ostrem A, Melbye H. Predictors of ICS/LABA prescribing in COPD patients: a study from general practice. BMC Fam Pract. 2014;15:42.